UCLA receives $1 million to fund breast cancer research

UCLA has received a $1 million donation from Revlon to support the Revlon/UCLA Women's Cancer Research Program and continue UCLA's commitment to eradicate women's cancers. The gift was announced last week by Revlon chairman Ronald O. Perelman and global brand ambassador Halle Berry at an event honoring JCCC member Dr. Dennis Slamon for his outstanding achievements in cancer research and the development of Herceptin. Read more >

Latest News

Experimental drug discovery could eventually treat common blood cancer

UCLA scientists have developed a first-of-its-kind experimental treatment to prevent myeloma cells (which accumulate in the bone marrow and push out healthy blood cells from growing) to slow or stop the spread of the disease. Led by JCCC member Dr. Alan Lichtenstein, the one-year study found that an experimental drug called compound 11, working in tandem with bortezomib, targeted a specific protein to stop cancer cells in the bone marrow from replicating.

Read more >

Twice the Impact

As JCCC members, you know the power of philanthropy in accelerating the pace of cancer research—through seed grants, strategic investment in members and funds for new technology. Now, thanks to a generous JCCF donor, your unrestricted online gift will be matched dollar-for-dollar! This is the perfect time for you, along with your friends, family and other supporters to have double the impact. Give by June 30 to have your gift matched and help ensure the Cancer Center's continued success.

Common cooking spice can increase drug effectiveness in head and neck cancer, study finds

A new study led by JCCC members Drs. Marilene Wang and Eri Srivatsan has discovered that a synthetic version of a commonly-used cooking spice called curcumin significantly reduced resistance to the well-known chemotherapy drug Cisplatin in head and neck cancer cells. They found that the spice uses an alternate pathway to Cisplatin, and resistant cell lines do not respond to the typical pathway that Cisplatin would go through, allowing it to kill resistant cells.

Read more >
Social Networking Tools

- JCCC is on Twitter, Facebook and YouTube. Learn how to follow us and stay connected!

Pub It: Update Your Member Profile Publications

As a JCCC member, your online profile is often the first stop for patients, staff, fellow researchers and potential donors to learn about your research and accomplishments. Did you know that you can highlight up to five publications of your choice on your profile? Click here to read the Member Profile Guidelines and learn how to update your pubs and all information on your profile today.

© 2014 UCLA Jonsson Comprehensive Cancer Center. All Rights Reserved.
Terms & Conditions | Privacy Practices | About the JCCC Website

Have feedback on this newsletter? Direct your questions and comments to: newsletter@mednet.ucla.edu